Mpox outbreak in a cluster of hospitals at Riyadh, Saudi Arabia 2022-2023: clinical presentation, risk factors, and preventive measures.

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Chemotherapy Pub Date : 2024-10-24 DOI:10.1080/1120009X.2024.2412440

Nadeem Gul Dar, Sarah H Alfaraj, Khulood Naser Alboqmy, Nazia Khanum, Faleh Alshakrah, Hassan Abdallah, Mohammad Hosni Badawi, Mwayad F Alqunisi, Zeidan A Zeidan, Shamna Jalalindin, Saly Simon, Omar Owaidh Alharbi, Zaki Abdallah, Dhivya Bhaskaran, Ziad A Memish

{"title":"Mpox outbreak in a cluster of hospitals at Riyadh, Saudi Arabia 2022-2023: clinical presentation, risk factors, and preventive measures.","authors":"Nadeem Gul Dar, Sarah H Alfaraj, Khulood Naser Alboqmy, Nazia Khanum, Faleh Alshakrah, Hassan Abdallah, Mohammad Hosni Badawi, Mwayad F Alqunisi, Zeidan A Zeidan, Shamna Jalalindin, Saly Simon, Omar Owaidh Alharbi, Zaki Abdallah, Dhivya Bhaskaran, Ziad A Memish","doi":"10.1080/1120009X.2024.2412440","DOIUrl":null,"url":null,"abstract":"<p><p>This study investigated the Mpox outbreak that occurred in a health cluster of three hospitals in Riyadh, Saudi Arabia, involving 97 patients diagnosed between May and December 2023. Among them, 48% were Saudi nationals, 94% were men, and 73% were under 35 years old. While sexual activity was a potential transmission mode, only 38% of patients reported it. All patients were presented with skin lesions and common symptoms like fever, headaches, and itching, with two being HIV positive. Genotyping revealed all samples were from subclade IIb (West Africa clade). Unlike previous outbreaks, rashes and systemic symptoms emerged simultaneously without a prodromal phase. Stringent infection control measures kept healthcare workers safe, although underreporting of sexual behavior may limit the study's findings. This highlights the need for Mpox consideration in young individuals with skin lesions.</p>","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1120009X.2024.2412440","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

This study investigated the Mpox outbreak that occurred in a health cluster of three hospitals in Riyadh, Saudi Arabia, involving 97 patients diagnosed between May and December 2023. Among them, 48% were Saudi nationals, 94% were men, and 73% were under 35 years old. While sexual activity was a potential transmission mode, only 38% of patients reported it. All patients were presented with skin lesions and common symptoms like fever, headaches, and itching, with two being HIV positive. Genotyping revealed all samples were from subclade IIb (West Africa clade). Unlike previous outbreaks, rashes and systemic symptoms emerged simultaneously without a prodromal phase. Stringent infection control measures kept healthcare workers safe, although underreporting of sexual behavior may limit the study's findings. This highlights the need for Mpox consideration in young individuals with skin lesions.

查看原文本刊更多论文

2022-2023 年沙特阿拉伯利雅得一组医院爆发的麻风腮疫情：临床表现、风险因素和预防措施。

本研究调查了沙特阿拉伯利雅得由三家医院组成的医疗群中爆发的麻风腮疫情，共有97名患者在2023年5月至12月期间确诊。其中 48% 为沙特国民，94% 为男性，73% 年龄在 35 岁以下。虽然性活动是一种潜在的传播方式，但只有 38% 的患者报告过。所有患者都有皮损和发烧、头痛、瘙痒等常见症状，其中两名患者的艾滋病毒呈阳性。基因分型显示，所有样本均来自亚支系 IIb（西非支系）。与以往疫情不同的是，皮疹和全身症状是同时出现的，没有前驱期。严格的感染控制措施保证了医护人员的安全，但性行为报告不足可能会限制研究结果。这凸显了对有皮损的年轻人考虑麻疹病毒的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Chemotherapy 医学-药学

CiteScore

3.70

自引率

0.00%

发文量

144

审稿时长

6-12 weeks

期刊介绍： The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy. The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs. Specific areas of focus include, but are not limited to: · Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents; · Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy; · Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents; · The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs; · Drug interactions in single or combined applications; · Drug resistance to antimicrobial and anticancer drugs; · Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research; · Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs; · Pharmacogenetics and pharmacogenomics; · Precision medicine in infectious disease therapy and in cancer therapy; · Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.